trial

HARMONY OUTCOMES

What is HARMONY OUTCOMES?

HARMONY OUTCOMES tested albiglutide for cardiovascular outcomes in 9,463 people who had type 2 diabetes alongside existing cardiovascular disease (Hernandez et al., Lancet 2018).

MACE came down 22%. GSK had withdrawn albiglutide from global markets a year before those results reached print, and the decision was commercial rather than clinical.

Related reading: HARMONY OUTCOMES: A Win for a Withdrawn Drug

GLP Watchdog writes these definitions from FDA labels and peer-reviewed PubMed literature.

Where HARMONY OUTCOMES comes up on this site

Other terms under trial

Where the evidence lives